Analysts Set Biohaven Ltd. (NYSE:BHVN) PT at $61.92

Biohaven Ltd. (NYSE:BHVN) has received a consensus recommendation of “Buy” from the fourteen analysts that are presently covering the company, Marketbeat reports. Thirteen investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $61.92.

A number of analysts recently commented on BHVN shares. UBS Group dropped their target price on shares of Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. Piper Sandler boosted their target price on shares of Biohaven from $66.00 to $76.00 and gave the stock an “overweight” rating in a report on Monday, September 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a report on Friday, October 4th. Leerink Partners boosted their target price on shares of Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Finally, Morgan Stanley assumed coverage on shares of Biohaven in a research report on Wednesday, July 24th. They issued an “overweight” rating and a $58.00 target price on the stock.

Insider Transactions at Biohaven

In related news, Director John W. Childs purchased 28,400 shares of the firm’s stock in a transaction that occurred on Thursday, July 18th. The stock was acquired at an average price of $35.67 per share, for a total transaction of $1,013,028.00. Following the completion of the acquisition, the director now owns 2,339,741 shares of the company’s stock, valued at $83,458,561.47. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director John W. Childs purchased 28,400 shares of the business’s stock in a transaction dated Thursday, July 18th. The stock was bought at an average price of $35.67 per share, for a total transaction of $1,013,028.00. Following the purchase, the director now owns 2,339,741 shares of the company’s stock, valued at $83,458,561.47. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John W. Childs acquired 21,052 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were bought at an average cost of $47.50 per share, for a total transaction of $999,970.00. Following the acquisition, the director now directly owns 21,052 shares in the company, valued at $999,970. The disclosure for this purchase can be found here. Insiders have bought 54,452 shares of company stock valued at $2,233,948 over the last ninety days. 16.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Biohaven

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in Biohaven by 280.5% in the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock worth $345,031,000 after acquiring an additional 4,650,702 shares during the last quarter. Darwin Global Management Ltd. purchased a new position in Biohaven in the 1st quarter worth approximately $80,776,000. Farallon Capital Management LLC raised its holdings in Biohaven by 181.4% in the 2nd quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock worth $78,028,000 after acquiring an additional 1,449,000 shares during the last quarter. Armistice Capital LLC raised its holdings in Biohaven by 74.8% in the 2nd quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock worth $48,489,000 after acquiring an additional 597,705 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in Biohaven by 166.8% in the 2nd quarter. American Century Companies Inc. now owns 511,237 shares of the company’s stock worth $17,745,000 after acquiring an additional 319,634 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors.

Biohaven Price Performance

NYSE BHVN opened at $50.73 on Friday. Biohaven has a 12 month low of $25.97 and a 12 month high of $62.21. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of -7.43 and a beta of 1.31. The company’s fifty day moving average price is $42.56 and its two-hundred day moving average price is $40.01.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($3.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92). As a group, analysts anticipate that Biohaven will post -8.82 EPS for the current year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.